Tiny study checks heart drug safety in india
NCT ID NCT06086353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of a drug called Tafamidis (brand name VyndaMx) in 6 people in India with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). In ATTR-CM, faulty proteins build up in the heart and make it harder to pump blood. Researchers tracked side effects for 6 months after patients started taking the drug. The goal was simply to see if the drug is safe in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tafamidis (VyndaMx) capsules
What this could lead to
If successful, this study could confirm that Tafamidis is safe for use in Indian patients with ATTR-CM, supporting its continued use.
What could go wrong
This was a very small study (only 6 participants) and only looked at safety, not effectiveness. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIG Hospital
Hyderabad, 500032, India
-
Max Super Speciality Hospital
New Delhi, 110017, India
-
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka, 560069, India